A Phase 2/3 Open-Label Study to Evaluate the Safety and Immunogenicity of an XBB.1.5 (Omicron Subvariant) SARS CoV-2 rS Vaccine.
Condition: COVID-19 Interventions: Biological: XBB.1.5 Vaccine (Booster); Biological: XBB.1.5 Vaccine (single dose) Sponsor: Novavax Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
COVID Transmission and Morbidity in Malawi
Conditions: SARS CoV 2 Infection; SARS CoV 2 Vaccination Intervention: Sponsors: Boston University; National Institute of Allergy and Infectious Diseases (NIAID); Malaria Alert Center, Kamuzu University of Health Sciences; Burnet Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines
Condition: COVID-19 Interventions: Biological: NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine; Biological: Prototype/XBB.1.5 Bivalent Vaccine (5 µg) Sponsor: Novavax Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
Condition: COVID-19 Interventions: Biological: mRNA-CR-04 vaccine 10μg; Biological: mRNA-CR-04 vaccine 30μg; Biological: mRNA-CR-04 vaccine 100μg; Drug: Placebo Sponsor: GlaxoSmithKline Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
COVID Transmission and Morbidity in Malawi
Conditions: SARS CoV 2 Infection; SARS CoV 2 Vaccination Intervention: Sponsors: Boston University; National Institute of Allergy and Infectious Diseases (NIAID); Malaria Alert Center, Kamuzu University of Health Sciences; Burnet Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines
Condition: COVID-19 Interventions: Biological: NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine; Biological: Prototype/XBB.1.5 Bivalent Vaccine (5 µg) Sponsor: Novavax Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
Condition: COVID-19 Interventions: Biological: mRNA-CR-04 vaccine 10μg; Biological: mRNA-CR-04 vaccine 30μg; Biological: mRNA-CR-04 vaccine 100μg; Drug: Placebo Sponsor: GlaxoSmithKline Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
COVID Transmission and Morbidity in Malawi
Conditions: SARS CoV 2 Infection; SARS CoV 2 Vaccination Intervention: Sponsors: Boston University; National Institute of Allergy and Infectious Diseases (NIAID); Malaria Alert Center, Kamuzu University of Health Sciences; Burnet Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines
Condition: COVID-19 Interventions: Biological: NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine; Biological: Prototype/XBB.1.5 Bivalent Vaccine (5 µg) Sponsor: Novavax Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
Condition: COVID-19 Interventions: Biological: mRNA-CR-04 vaccine 10μg; Biological: mRNA-CR-04 vaccine 30μg; Biological: mRNA-CR-04 vaccine 100μg; Drug: Placebo Sponsor: GlaxoSmithKline Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
COVID Transmission and Morbidity in Malawi
Conditions: SARS CoV 2 Infection; SARS CoV 2 Vaccination Intervention: Sponsors: Boston University; National Institute of Allergy and Infectious Diseases (NIAID); Malaria Alert Center, Kamuzu University of Health Sciences; Burnet Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials